| Name | MS4078 |
| Description | MS4078 is an inhibitor and aplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 19 nM for binding affinity to ALK. |
| In vitro | MS4078 effectively inhibits cancer cell proliferation by inducing ALK protein degradation via a cereblon and proteasome-dependent mechanism. In SU-DHL-1 cells, it shows an IC50 of 33 nM, and potently reduces ALK fusion protein levels, inhibits ALK auto-phosphorylation, and downstream STAT3 phosphorylation in a concentration-dependent manner. It specifically reduces NPM-ALK protein levels in SU-DHL-1 cells (DC50 of 11 nM) and EML4-ALK protein levels in NCI-H2228 cells (DC50 of 59 nM). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : < 10 mg/mL (10.94 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
DMSO : 150 mg/mL (164.03 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (10.94 mM), Solution.
|
| Keywords | PROTACs | MS-4078 | MS4078 | MS 4078 | Inhibitor | inhibit | Cluster of differentiation 246 | Cereblon | CD246 | Anaplastic lymphoma kinase (ALK) | Anaplastic lymphoma kinase | ALK tyrosine kinase receptor | ALK |
| Inhibitors Related | Alectinib | ALKBH5-IN-5 | Alectinib hydrochloride | SB-431542 | RepSox | Bavdegalutamide | Crizotinib | dBET6 | ARV-825 | Brigatinib | Vepdegestrant | A 83-01 |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Multi-Target Compound Library | Angiogenesis related Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
